Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating deficits continued in key regions, and an operating loss was recorded due to delays in signing large contracts and other factors. The ordinary loss was due to foreign exchange losses and other factors. Meanwhile, order backlog increased as funding shifted to areas including cancer, central nervous system diseases and autoimmune diseases, improving the order environment.
There is a description of significant events and other matters related to the going concern assumption. However, based on the expected recognition of revenue and collection of cash from contracted order backlog, as well as its cash and deposits on hand, the company determined that no material uncertainty related to the going concern assumption exists. There are no applicable matters to disclose in the notes regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥3,739 million (YoY -23.0%) |
| Operating profit | ¥-1,280 million |
| Ordinary income | ¥-1,360 million |
| Profit attributable to owners of the parent | ¥-1,223 million |
| Net income per share | -¥54.18 |
| Equity ratio | End of the current fiscal period 24.7 / End of previous period 33.1 |
| Total assets | ¥10,427 million |
| Net assets | ¥2,577 million |
| Cash flows from operating activities | -1,033,884 Thousand yen |
| Cash flows from investing activities | 3,248 Thousand yen |
| Cash flows from financing activities | -427,937 Thousand yen |
| Cash and cash equivalents at end of period | 3,772,952 Thousand yen |
| Full-year earnings forecast | Net Sales ¥10,680 million (YoY +23.2%) / Operating profit ¥256 million / Ordinary income ¥250 million / Net income ¥180 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 8 Yen → 8 Yen(0.0%) |
| Regional sales | Japan 1,455,423 Thousand yen / United States 840,629 Thousand yen / Europe 876,960 Thousand yen / Asia 566,892 Thousand yen |
| Orders received and order backlog | Order backlog End of fiscal year ended March 2026 ¥11,673 million / End of the interim period for the fiscal year ending March 2027 ¥14,199 million / As of 16 November 2026 ¥15,780 million |
| Depreciation and amortization | 63,196 Thousand yen |
| Disclosure regarding the going concern assumption | There is a description of significant events and other matters related to the going concern assumption. However, based on the expected recognition of revenue and collection of cash from contracted order backlog, as well as its cash and deposits on hand, the company determined that no material uncertainty related to the going concern assumption exists. There are no applicable matters to disclose in the notes regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts, scheduled for 4 December 2026) |
| Issued Shares at Period-End | 24,740,000 Shares |
| Treasury Shares at Period-End | 2,153,569 Shares |
| Factors Behind Changes in Business Performance | Operating deficits continued in key regions, and an operating loss was recorded due to delays in signing large contracts and other factors. The ordinary loss was due to foreign exchange losses and other factors. Meanwhile, order backlog increased as funding shifted to areas including cancer, central nervous system diseases and autoimmune diseases, improving the order environment. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited continuing operating deficits in its key regions and the recording of an operating loss in the interim period due to delays in signing large contracts and other factors. It attributed the ordinary loss to foreign exchange losses and other factors. Meanwhile, it said the order environment had improved as funding shifted to other disease areas with the winding down of vaccine and therapeutic drug development.